FilingSEC EDGAR8-K
Evommune to Host Webcast on EVO570 and Immunology Portfolio
· SEC accepted
StageClinical-stage
Filing content
Evommune announced a webcast to discuss the development path of its oral VAV1-directed molecular glue degrader, EVO570, and the terms of its in-licensing agreement.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…